Related Experiment Video
Updated: Feb 13, 2026
Acute Myocardial Infarction in Rats
Published on: February 16, 2011
Effect of β-Blockers Beyond 3 Years After Acute Myocardial Infarction
Jin Joo Park1, Sun-Hwa Kim1, Si-Hyuck Kang1
1Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam, Korea.
Insights
Beta-blocker therapy after acute myocardial infarction (AMI) shows benefits at discharge, but late use beyond one year may not reduce mortality. Further trials are needed to confirm long-term benefits.
Area of Science:
- Cardiology
- Clinical Medicine
- Pharmacology
Background:
- Optimal duration of beta-blocker therapy post-acute myocardial infarction (AMI) remains undetermined.
- Evaluating the long-term impact of beta-blockers in AMI patients is crucial for treatment guidelines.
Purpose of the Study:
- To assess the late effects of beta-blocker therapy on 5-year all-cause mortality in patients following AMI.
- To determine if beta-blocker use at discharge, 1 year, or 3 years post-AMI influences long-term survival.
Main Methods:
- Retrospective analysis of 2592 consecutive AMI patients from June 2003 to February 2015.
- Examined beta-blocker prescription rates at discharge and at 1, 3, and 5 years post-AMI.
- Utilized Cox regression models to adjust for covariates and assess the association between beta-blocker use and 5-year mortality.
Main Results:
- Beta-blocker prescription rates decreased from 72% at discharge to 60% at 5 years post-AMI.
- Patients on beta-blockers had favorable characteristics and received more reperfusion therapy.
- Adjusted analysis revealed beta-blocker use at discharge significantly reduced 5-year mortality risk (HR 0.71, P=0.006).
- Beta-blocker prescriptions at 1 and 3 years post-AMI were not associated with reduced mortality.
Conclusions:
- The survival benefit of beta-blocker therapy after AMI appears limited to the first year.
- Late beta-blocker therapy initiated beyond one year post-AMI may not provide significant clinical benefits.
- Further clinical trials are warranted to investigate the efficacy of extended beta-blocker use in AMI patients.
Background:
The optimal duration of β-blocker therapy in patients with acute myocardial infarction (AMI) is unknown. We aimed to evaluate the late effect of β-blockers in patients with AMI.
Methods And Results:
We enrolled all consecutive patients who presented with AMI at Seoul National University Bundang Hospital, between June 3, 2003 and February 24, 2015. The primary end point was 5-year all-cause mortality, depending on the use of β-blockers at discharge, 1 year after AMI, and 3 years after AMI. Of 2592 patients, the prescription rates of β-blockers were 72%, 69%, 63%, and 60% at discharge and 1, 3, and 5 years after AMI, respectively. The patients who were receiving β-blocker therapy had more favorable clinical characteristics, such as younger age (62 versus 65 years; P<0.001). They received reperfusion therapy more often (92% versus 80%; P<0.001) than those without β-blocker prescription. In the univariate analysis, the patients with β-blocker prescription had lower 5-year mortality at all time points. In the Cox model after adjustment for significant covariates, β-blocker prescription at discharge was associated with a 29% reduced mortality risk (hazard ratio, 0.71; 95% confidence interval, 0.55-0.90; P=0.006); however, β-blocker prescriptions at 1 and 3 years after AMI were not associated with reduced mortality.
Conclusions:
The beneficial effect of β-blocker therapy after AMI may be limited until 1 year after AMI. Whether late β-blocker therapy beyond 1 year after AMI offers clinical benefits should be confirmed in further clinical trials.
Related Concept Videos
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
01:28Antihypertensive Drugs: Types of β-Blockers
01:22Heart Failure Drugs: β-Blockers
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:17Antihypertensive Drugs: Action of β1 Blockers
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers